Pasithea Therapeutics (KTTA) said Thursday that interim data from a phase 1 study showed that its experimental drug, PAS-004, was effective and safe in treating neurofibromatosis type 1 and other cancer indications.
The company said PAS-004's long half-life of about 70 hours enables once-daily or less frequent oral dosing compared with previous versions of the drug, which required twice-daily dosing and exhibited short half-lives.
Pasithea also said that the drug's pharmacokinetic profile indicated consistent plasma levels at a steady state, which may reduce the risk of toxicity related to peak concentrations.
The drug developer said that the study results support the advancement of PAS-004 into clinical trials for treating cutaneous and plexiform neurofibromas in NF1, as well as other MAPK-driven conditions.
The company plans to provide additional trial updates periodically as the trial progresses.
Shares of the company rose more than 63% in premarket activity Thursday.
Price: 6.2800, Change: +2.44, Percent Change: +63.33
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。